R. C. Zellars, S. G. Hilsenbeck, G. M. Clark, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: Journal of Clinical Oncology, Vol. 18, No 9, 1906-1913, (May) 2000
Randomized clinical trials have established that radiation therapy improves the local regional control and survival in selected breast cancer patients treated with mastectomy. However, only about 50% of patients will benefit from post-mastectomy irradiation and the remaining 50% still die with uncontrolled local-regional disease. Much effort has been made to identify breast cancer patients at greatest risk of local-regional failure and most likely to benefit from postmastectomy irradiation. Dr. Zellars and his colleagues examined the tumor suppressor gene p53 as a predictor of local-regional failure.
p53 levels were examined retrospectively in 1,530 breast cancer patients treated with mastectomy. In 259 patients, mastectomy was followed with adjuvant radiation therapy.
After a median follow-up of 62 months, the researchers found:
In this study, p53-positive breast cancers were strongly associated with an increased risk of local recurrence after mastectomy, regardless of adjuvant radiation treatment. This finding may help physicians to identify a subgroup of breast cancer patients who are at greater risk of local-regional failure and who therefore may benefit from more aggressive local management.
Sep 29, 2011 - For patients with breast cancer and polysomy 17, the true gene status of human epidermal growth factor receptor 2 (HER2) can be effectively determined by use of additional chromosome 17 fluorescent in situ hybridization studies for Smith-Magenis syndrome, retinoic acid receptor alpha, and tumor protein p53 genes, rather than the HER2-to-centromeric probe ratio, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Jan 23, 2012
Nov 29, 2014